Oncology

Itovebi (Inavolisib) Mechanism of Action in Treating Advanced Breast Cancer

by
a purple and black background with lots of small flowers

Itovebi is a potent kinase inhibitor that has gained attention in the treatment landscape for advanced breast cancer, particularly when used in combination with other therapeutic agents like palbociclib and fulvestrant. Its primary indication lies in targeting specific breast cancer subtypes, notably endocrine-resistant, PI3KCA-mutated, HR-positive, and HER2-negative breast cancer in adult patients. This specificity is … Read more

FDA Approves Lazcluze (Lazertinib) Tablets for Non-Small Cell Lung Cancer Treatment

by
a purple and black background with lots of small flowers

Lazcluze (Lazertinib) is the latest medical breakthrough in the ongoing fight against non-small cell lung cancer (NSCLC). Officially approved by the Food and Drug Administration (FDA) on August 19, 2024, Lazcluze offers a novel therapeutic option for patients diagnosed with this aggressive and often difficult-to-treat form of cancer. Its advent marks a significant milestone in … Read more